Table 1 Clinical characteristics of TCL patients
From: TNFAIP3 mutation may be associated with favorable overall survival for patients with T-cell lymphoma
Variables | JNU dataset | GDPH dataset | COSMIC dataset | GSE15842 dataset |
|---|---|---|---|---|
Number | 41 | 79 | 544 | 47 |
Gender, n (%) | – | – | ||
 Female | 19 (46.3) | 30 (38.0) | – | – |
 Male | 22 (53.7) | 49 (62.0) | – | – |
Age, y, mean ± SD | 48 ± 19 | 46 ± 19 | – | – |
Subtype, n (%)a | ||||
 AITL | 5 (12.2) | 18 (22.8) | 101 (18.6) | 0 (0.0) |
 ALCL | 1 (2.4) | 6 (7.6) | 19 (3.5) | 0 (0.0) |
 ATLL | 0 (0.0) | 0 (0.0) | 292 (53.7) | 0 (0.0) |
 CTCL | 1 (2.4) | 1 (1.3) | 73 (13.4) | 0 (0.0) |
 EATL | 1 (2.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
 HSTCL | 0 (0.0) | 1 (1.3) | 3 (0.6) | 0 (0.0) |
 MEITL | 0 (0.0) | 1 (1.3) | 0 (0.0) | 0 (0.0) |
 NKTCL | 15 (36.6) | 15 (19.0) | 7 (1.3) | 0 (0.0) |
 PTCL-NOS | 5 (12.2) | 18 (22.8) | 48 (8.8) | 47 (100%) |
 SPTCL | 1 (2.4) | 1 (1.3) | 0 (0.0) | 0 (0.0) |
 T-LBL | 9 (22.0) | 18 (22.8) | 0 (0.0) | 0 (0.0) |
 T-LGLL | 3 (7.3) | 0 (0.0) | 1 (0.2) | 0 (0.0) |
Country, n (%)a | ||||
 China | 41 (100) | 79 (100) | 0 (0.0) | 0 (0.0) |
 USA | 0 (0.0) | 0 (0.0) | 237 (43.6) | 0 (0.0) |
 Japan | 0 (0.0) | 0 (0.0) | 291 (53.5) | 0 (0.0) |
 Australia | 0 (0.0) | 0 (0.0) | 9 (1.7) | 0 (0.0) |
 Italy | 0 (0.0) | 0 (0.0) | 5 (0.9) | 0 (0.0) |
 Germany | 0 (0.0) | 0 (0.0) | 0 (0.0) | 47 (100%) |
 Unknown | 0 (0.0) | 0 (0.0) | 4 (0.7) | 0 (0.0) |
Detection method | PCR + sanger sequencing | Exome sequencing | – | SNP array |
Covered area | Non-CDS and CDS | CDS | CDS | – |
Follow up, m, median (range) | 23.37 (0.23 to 157.83) | – | – | – |
Status (alive/dead), n | 22/19 | – | – | – |